In draft guidance published this week, NICE has said that a migraine treatment made by Novartis has is “not a cost-effective use of NHS resources”.
The guidance looks at erenumab (also called Aimovig) for preventing chronic and episodic migraine in adults who have 4 episodes or more of migraine every month and where at least 3 other preventive treatments haven’t worked.
Costing around £5,000 per year, erenumab is the first treatment to target the process by which proteins cause blood vessels in the brain to swell, leading to the symptoms of migraine.
The evidence shows that erenumab is a clinically effective treatment. However, the NICE committee concluded that the clinical trial evidence for the drug doesn’t fully reflect patients seen in the NHS and nor does it include all the relevant comparisons with other drugs and outcomes.
Because of this the cost-effectiveness estimates for erenumab are higher than what NICE usually considers to be acceptable when there is substantial uncertainty in the evidence.
Meindert Boysen, Director of the Centre for Health Technology Evaluation at NICE, said: “Migraine is a debilitating condition that significantly affects quality of life and the committee heard from patient experts that well-tolerated treatments are needed.
“It’s therefore disappointing that we’ve not been able to make a positive recommendation for erenumab.
“Erenumab is a promising new preventive treatment for migraine that has been shown to be clinically effective compared with best supportive care.
“However, there was not enough evidence to suggest that it is more effective than botulinum toxin type A for people with chronic migraine, which NICE already recommends.
“And for both the chronic and episodic migraine populations there was no evidence to show that erenumab is effective in the long-term in people for whom 3 previous preventive treatments had failed.
“We will work with the company to ensure that they are given every opportunity to address the issues highlighted in these provisional recommendations.”